181 related articles for article (PubMed ID: 35604526)
1. Management Impact of Metachronous Oligometastatic Disease Identified on
Anderson RC; Velez EM; Jadvar H
Mol Imaging Biol; 2022 Dec; 24(6):920-927. PubMed ID: 35604526
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
5. Impact of
Andriole GL; Scarsbrook AF; Savir-Baruch B;
Urol Oncol; 2023 Jun; 41(6):293.e1-293.e7. PubMed ID: 37121865
[TBL] [Abstract][Full Text] [Related]
6. Effect of hormonal therapy on
Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
[TBL] [Abstract][Full Text] [Related]
7. [
Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
10. A bicentric retrospective analysis of clinical utility of
Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
[TBL] [Abstract][Full Text] [Related]
11.
Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
[TBL] [Abstract][Full Text] [Related]
12. Effect of
Scarsbrook AF; Bottomley D; Teoh EJ; Bradley KM; Payne H; Afaq A; Bomanji J; van As N; Chua S; Hoskin P; Chambers A; Cook GJ; Warbey VS; Han S; Leung HY; Chau A; Miller MP; Gleeson FV;
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):316-324. PubMed ID: 32068113
[TBL] [Abstract][Full Text] [Related]
13.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
14. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
16. Positivity Rate of [
Bulbul JE; Grybowski D; Lovrec P; Solanki AA; Gabriel MS; Wagner RH; Savir-Baruch B
Mol Imaging Biol; 2022 Feb; 24(1):42-49. PubMed ID: 34480289
[TBL] [Abstract][Full Text] [Related]
17. Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
Lawal IO; Marcus C; Schuster DM; Goyal S; Adediran OA; Dhere VR; Joshi SS; Abiodun-Ojo OA; Master VA; Patel PR; Fielder B; Goodman M; Shelton JW; Kucuk O; Hershatter B; Halkar RK; Jani AB
Clin Nucl Med; 2023 Apr; 48(4):e153-e159. PubMed ID: 36754362
[TBL] [Abstract][Full Text] [Related]
18. Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center.
Müller PJ; Dietlein M; Kobe C; Heidenreich A; Drzezga A
Nuklearmedizin; 2022 Aug; 61(4):314-324. PubMed ID: 35388442
[TBL] [Abstract][Full Text] [Related]
19. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract][Full Text] [Related]
20.
Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
